Drug Profile
Filanesib - Array BioPharma
Alternative Names: ARRY-520; Filanesib-hydrochlorideLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Amides; Antineoplastics; Fluorobenzenes; Small molecules; Thiadiazoles
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 23 Mar 2020 PETHEMA Foundation, Array Biopharma and Celgene completes a phase I/II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Spain (NCT02384083)
- 03 Feb 2020 Discontinued - Phase-I for Solid tumours in USA (IV)
- 03 Feb 2020 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)